749 results on '"Vandekerckhove, Linos"'
Search Results
2. Mapping bacterial extracellular vesicle research: insights, best practices and knowledge gaps
3. Spiroplasma infection as a cause of severe congenital keratouveitis, cataract and glaucoma
4. Implementation of long‐acting cabotegravir and rilpivirine: primary results from the perspective of staff study participants in the Cabotegravir And Rilpivirine Implementation Study in European Locations
5. Staging of immuno-virological dynamics during acute HIV infection in a Belgian prospective cohort study
6. Potent latency reversal by Tat RNA-containing nanoparticle enables multi-omic analysis of the HIV-1 reservoir
7. Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials
8. Integrating artificial intelligence-based epitope prediction in a SARS-CoV-2 antibody discovery pipeline: caution is warranted
9. In-depth virological and immunological characterization of HIV-1 cure after CCR5Δ32/Δ32 allogeneic hematopoietic stem cell transplantation
10. Influence of UGT1A1 and SLC22A6 polymorphisms on the population pharmacokinetics and pharmacodynamics of raltegravir in HIV-infected adults: a NEAT001/ANRS143 sub-study
11. Targeted plasma proteomics identifies MICA and IL1R1 proteins associated with HIV-1 reservoir size
12. Dynamics of virological and immunological markers of HIV persistence after allogeneic haematopoietic stem-cell transplantation in the IciStem cohort: a prospective observational cohort study
13. Loss of GM-CSF-dependent instruction of alveolar macrophages in COVID-19 provides a rationale for inhaled GM-CSF treatment
14. Long non-coding RNAs and latent HIV - A search for novel targets for latency reversal.
15. People with HIV have higher percentages of circulating CCR5+ CD8+ T cells and lower percentages of CCR5+ regulatory T cells
16. Author Correction: Organ-specific genome diversity of replication-competent SARS-CoV-2
17. Development of human innate immune responses in a humanized mouse model expressing four human myelopoiesis transgenes.
18. Repeated COVID-19 mRNA-based vaccination contributes to SARS-CoV-2 neutralizing antibody responses in the mucosa.
19. MX2 forms nucleoporin-comprising cytoplasmic biomolecular condensates that lure viral capsids.
20. Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021
21. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial
22. Update on human herpesvirus 7 pathogenesis and clinical aspects as a roadmap for future research
23. Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial
24. CD32+CD4+ memory T cells are enriched for total HIV-1 DNA in tissues from humanized mice
25. Implementation of long-acting cabotegravir and rilpivirine: primary results from the perspective of staff study participants in the Cabotegravir And Rilpivirine Implementation Study in European Locations
26. Longitudinal patterns of inflammatory mediators after acute HIV infection correlate to intact and total reservoir
27. IRF7 and RNH1 are modifying factors of HIV-1 reservoirs: a genome-wide association analysis
28. In-depth single-cell analysis of translation-competent HIV-1 reservoirs identifies cellular sources of plasma viremia
29. PCIP-seq: simultaneous sequencing of integrated viral genomes and their insertion sites with long reads
30. Organ-specific genome diversity of replication-competent SARS-CoV-2
31. Rapid viral rebound after analytical treatment interruption in patients with very small HIV reservoir and minimal on-going viral transcription
32. During Stably Suppressive Antiretroviral Therapy Integrated HIV-1 DNA Load in Peripheral Blood is Associated with the Frequency of CD8 Cells Expressing HLA-DR/DP/DQ
33. Dependence on the CCR5 Coreceptor for Viral Replication Explains the Lack of Rebound of CXCR4-Predicted HIV Variants in the Berlin Patient
34. Rethinking IL-1 Antagonism in Respiratory Viral Infections: A Role for IL-1 Signaling in the Development of Antiviral T Cell Immunity
35. A truncated HIV Tat demonstrates potent and specific latency reversal activity
36. HIV-PULSE: a long-read sequencing assay for high-throughput near full-length HIV-1 proviral genome characterization
37. Sniffing out safety: canine detection and identification of SARS-CoV-2 infection from armpit sweat
38. Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial
39. A complement atlas identifies interleukin-6–dependent alternative pathway dysregulation as a key druggable feature of COVID-19
40. Integrative assessment of total and intact HIV-1 reservoir by a five-region multiplexed Rainbow digital PCR assay
41. No Significant Association between 25-OH Vitamin D Status and SARS-CoV-2 Antibody Response after COVID-19 Vaccination in Nursing Home Residents and Staff
42. Gut dysbiosis associates with cytokine production capacity in viral-suppressed people living with HIV
43. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial
44. Underestimated effect of intragenic HIV-1 DNA methylation on viral transcription in infected individuals
45. Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial
46. Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients
47. A truncated HIV Tat demonstrates potent and specific latency reversal activity
48. A complement atlas identifies interleukin-6–dependent alternative pathway dysregulation as a key druggable feature of COVID-19
49. Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials
50. In-vitro viral suppressive capacity correlates with immune checkpoint marker expression on peripheral CD8+ T cells in treated HIV-positive patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.